As I predicted, Mylan has expanded the EpiPen recall to now include additional lots distributed in the U.S. and other markets in consultation with the U.S. Food and Drug Administration (FDA). The expanded voluntary recall is being initiated in the U.S. and will also extend to additional markets in Europe, Asia, North and South America. In contrast to the first recall announcement that related only to the 0.3 mg injector, this recall now impacts both the 0.3 mg and 0.15 mg strengths of EpiPen Auto-Injector.
Mylan states in the press release that none of the recalled lots include the authorized generic for EpiPen Auto-Injector, which is also manufactured by Meridian Medical Technologies. This seems extremely strange to me, unless the defect relates to the label, since the generic is exactly the same device, just without the label. I think Mylan is trying to boost sales of the generic before they get recalled too.
Please share this post using the buttons below or by copying and pasting this link: http://blog.onespotallergy.com/2017/03/epipen-recall-extends-worldwide/
To read the press release regarding the expanded recall included the affected lot numbers and expiry dates, click here.
To read my previous article about the recall, click here.
Hello Elizabeth
You suspected/predicted right. The issue still seems vague. I also find it strange that the generic version is not impacted. It might be their way to divert from the bad press of overly expensive branded versions and boosting the sales of the generic one.
I am concerned that we only have one brand in this market so they control it. It takes years to get to market so we are stuck with them until a brave firm wants to take this one.
Jennifer